Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

This study has been completed.
Sponsor:
Collaborator:
UCB Pharma
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00299494
First received: March 2, 2006
Last updated: October 6, 2015
Last verified: October 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2014
  Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: July 21, 2015
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):